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Objective 
To rank outcomes identified as important to patients with psoriatic arthritis and examine their 
representation in existing composite measures. 
 
Methods 
Seven Nominal Group Technique (NGT) meetings took place at four hospital sites. Two sorting 
rounds were conducted to generate a shortlist of outcomes followed by a group discussion and 
final ranking. In the final ranking round patients were given 15 points each and asked to rank 
their top five outcomes from the shortlist. The totals were summed across the seven NGT 
groups and are presented as a percentage of the maximum possible priority score. 
 
Results 
Thirty one patients took part;16 men and 15 women, the mean age was 54 (range 24-77; 
standard deviation (SD) 12.2), the mean disease duration was 10.3 years (range 1 - 40; SD 9.2) 
and mean HAQ: 1.15 (range 0 - 2.63; SD 0.7). The highest ranked outcomes which patients 
wished to see from treatment were pain with 93 points (20.0%), fatigue 62 (13.3%), physical 
fitness 33 (7.1%), halting/ slowing damage 32 (6.9%) and quality of life/ wellbeing 29 (6.2%). 
Reviewing existing composite measures for psoriatic arthritis demonstrated that no single 
measure adequately captures all these outcomes. 
 
Conclusion  
Pain and fatigue were ranked as the outcomes most important to patients receiving treatment 
for PsA and are not well represented within existing composite measures. Future work will 
focus on validating composite measures modified to capture outcomes important to patients.  
 
  
Introduction  
Psoriatic arthritis (PsA) is an inflammatory arthritis affecting up to 20% of people with 
psoriasis.1 PsA is now well recognised to be progressive and destructive in the majority with 
considerable impact in quality of life and there is building evidence from observational studies 
that delay to diagnosis is associated with worse radiographic and functional outcome.2-4 This 
has prompted the hypothesis that early detection and treatment may improve outcome in the 
long term for patients. The ‘early detection to improve outcome in patients with undiagnosed 
psoriatic arthritis’ (PROMPT) study is a programme of studies to investigate the effect of 
enhanced surveillance for the early detection of arthritis amongst patients with psoriasis (RP-
PG-1212-20007). An important aspect of this study is to assess outcomes that are meaningful 
to patients.  
 
Considerable efforts have been made in recent years to improve the assessment of treatment 
response in PsA. Work within the Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA) and Outcome measures in Rheumatology (OMERACT) led to 
the development of a core set of domains of disease to be assessed in Randomised Controlled 
Trials (RCT’s) and Longitudinal Observational Studies (LOS) in 2006,5 recently updated in 
2016.6 There is however no consensus as yet on the optimal method for assessing treatment 
response.7, 8 It is well established that PsA may affect many domains including arthritis, 
enthesitis, dactylitis, spondylitis, uveitis and other extra articular manifestations such as the 
metabolic syndrome. There have been efforts to develop a composite outcome measure of 
disease activity to capture all aspects of PsA in a continuous activity measure. It is important 
to distinguish an activity measure from a response criteria such as the Minimal Disease Activity 
(MDA)9, PsA response criteria (PsARC)10, 11 or the American College of Rheumatology 
(ACR)12 criteria that defines a disease state that is either achieved or not. A disease activity 
measure has the benefit of grading response and tracking of activity over time, furthermore cut 
points of high, moderate, low disease activity and remission can be developed to derive a 
response criteria. An activity measure is also distinct from an impact of disease measure, such 
as the Psoriatic Arthritis Impact of Disease (PSAID), which more widely covers concepts of 
activities and participation.   
 
Several candidate activity measures have now been developed including the Composite 
Psoriatic Arthritis Disease Activity Index (CPDAI),13 GRACE measure (initially named the 
Arithmetic Mean of Desirability Function- AMDF then re-named the GRACE after the original 
development study), Psoriatic Arthritis Disease Activity Score (PASDAS)14 and Disease 
Activity in Psoriatic Arthritis (DAPSA)15. It has become apparent that these measures were 
developed with little patient involvement. This raises the issue that without representation of 
the lived experience of PsA through patient involvement we may be missing important aspects 
of disease thereby calling into question the validity of the composites.16  
 
As part of the PROMPT programme we set out to establish whether existing composite activity 
measures capture outcomes of treatment important to patients or whether modifications may 
be necessary. Any modified versions would need validation in a prospective study and 
shortened, more feasible versions derived (based on sensitivity to change) for use in routine 
care. The first stage previously reported was to identify which outcomes from treatment were 
thought important by patients in a UK multicentre focus group study.17 Qualitative data 
captured many outcomes important to patients, ranging from specific physical symptoms to the 
psychological, social and emotional impact on wellbeing and daily life. The objective of this 
present study was to rank these outcomes identified as important to patients and examine their 
representation in existing composite measures. 
 
Materials and Methods: 
 Nominal Group Technique 
A Nominal Group Technique (NGT) was applied in order for patients to rank the previously 
identified outcomes in relation to importance. A NGT is a structured group process with a focus 
on solution generation and decision-making.  It encourages contributions from all participants 
by asking each individual for their opinion and their vote in the ranking exercise. To ensure an 
appropriately wide range of views and experience, patients who took part in the initial focus 
group studies to identify domains17  were not eligible to take part in this present NGT ranking 
study.  
 
Seven NGT groups took place at four hospital sites in Bristol, Bath, Stoke and Weston. Patients 
were identified from routine clinic appointments by their treating physician. To be eligible to 
take part patients were over 18 years old, have a physician diagnosis of PsA and have sufficient 
English language to participate in discussions. Efforts were made to recruit a sample of patients 
with a spectrum of phenotype and activity.  
 
Prior to the start of the nominal groups, patients were asked to complete data on demographics, 
medications, and a Health Assessment Questionnaire score (HAQ)18 as a measure of physical 
function. Nominal groups lasted for approximately one hour, were co-facilitated by two 
members of the study team (ED and SH) and were audio-recorded to keep an audit trail of the 
process. The nominal groups began with patients individually sorting a pack of laminated cards 
listing the 68 outcomes from previous UK focus group studies,17 as well as five additional 
outcomes generated from a concurrent international focus group study.6 Data from both these 
focus group studies contributed to the updated Outcome Measures in Rheumatology 
(OMERACT) psoriatic arthritis core set of domains.6 The questions asked in these focus group 
studies addressed the same themes but exact wording differed: 
UK focus groups were asked: 
 Which symptoms have the most effect on your well-being? 
 What do you want from your treatment? 
 What are the benefits and drawbacks of treatment for you personally?  
 ‘How do you know when you are in a flare?’ 
International focus groups were asked: 
 How does PsA affect your life? 
 Has your life changed since PsA? 
 How do you know you are in flare/remission? 
 
In round one of the NGT patients were asked to rank with the instruction: ‘What outcomes 
would you want from a treatment for your psoriatic arthritis?’ Outcomes were categorised into 
four groups: not important/not applicable, important, very important, and most important. In 
round two, patients then identified the top five of their “most important outcomes” and these 
were shared with the group, listed on a board and each one discussed and debated by the group, 
supported by facilitators. In round three, patients were asked to individually rank the top 
outcomes from the group list and overall ranking scores were calculated. The five top outcomes 
scored five points down to one according to priority order. Points were then summed across all 
seven nominal groups giving a potential total of 465 points. Data are represented as total points 
and percentage of the maximum possible score. 
 
This study was approved by the National Research Ethics Service Committee North West-
Haydock (reference: 15/NW/0609) and has been conducted in accordance with the Declaration 
of Helsinki. All participants signed informed consent.  
 
Representation in existing composite measures  
The final ranked outcomes from the NGT were then mapped against those included in the 
CPDAI, PASDAS, DAPSA and GRACE by one investigator (WT). These data were then 
presented at an investigators meeting to discuss; a) how each outcome was represented in the 
existing composite measures, b) identify the highest ranked outcomes important to patients that 
were missing and c) discuss which instruments could be added to capture these important 
missing domains to modify composites. The PASDAS, which was derived through a regression 
analysis and as such cannot be modified retrospectively, has been included in this study for 
completeness. The CPDAI, GRACE and DAPSA are modular and hence amenable to 
modification. At the mapping meeting there were three Patient Research Partners (PRP’s) MB, 
JJ, JL, four clinicians; WT, NM, OFG, PH and two qualitative researchers, ED and SH.  
 Composite measures 
The Composite Psoriatic Arthritis Disease Activity Index (CPDAI).13 The CPDAI measures 
disease activity in five domains: peripheral joints [68 tender and 66 swollen joints, and Health 
Assessment Questionnaire (HAQ)]19, skin [Psoriasis Areas and Severity Index- (PASI)20 and 
Dermatology Life Quality Index (DLQI)21], enthesitis (Leeds Enthesitis Count22 and HAQ), 
dactylitis (number of tender dactylitic digits and HAQ), and spine [Bath Ankylosing 
Spondylitis Disease Activity Score (BASDAI)23 and Ankylosing Spondylitis QOL index 
ASQoL)24]. Within each domain, severity is graded as 0 (none), 1 (mild), 2 (moderate), and 3 
(severe), according to predefined cut offs. 
 The GRACE measure.14 The GRACE measure is derived from the tender and swollen joint 
count, HAQ, patient global, skin and joint VAS scores, PASI and Psoriatic Arthritis Quality of 
Life (PsAQoL). Scores are transformed into linear functions ranging from 0 (totally 
unacceptable state) to 1 (normal) based on established desirability functions.14 The eight 
transformed variables are then combined using the arithmetic mean giving a score from 0 to 1 
the GRACE measure is a transformed version where scores range from 0 (low disease activity) 
to 10 (high disease activity). 
 
The Disease Activity in Psoriatic Arthritis (DAPSA).15 The DAPSA is a measure derived from 
the 68 tender and 66 swollen joint count, C Reactive Protein (CRP), patient global and pain 
visual analogue scales.  
 
Psoriatic Arthritis Disease Activity Score (PASDAS).14 The PASDAS is a weighted index 
comprising assessments of joints, function, acute-phase response, quality of life (QOL), and 
patient and physician global by Visual Analogue Scale (VAS).  
 
 
Results 
Nominal Group Technique 
Thirty one patients took part in seven nominal groups at four hospital sites. There were a total 
of 16 men and 15 women, the mean age was 54 (range 24-77; standard deviation SD 12.2), the 
mean disease duration was 10.3 years (range 1-40; SD 9.2) and mean HAQ: 1.15 (range 0-
2.63; SD 0.7). Patients had current or previous disease activity in the following domains; 
peripheral arthritis (n=29), psoriasis (27), spondyloarthritis (5), enthesitis (5), uveitis (1). The 
68 outcomes important to patients discussed in round one are listed in Table 1.  The round two 
shortlists from each of the seven NGT’s are reported in Table 2. The final ranking of outcomes 
important to patients from round three are listed in Table 3. The top five ranked outcomes from 
treatment were pain with 93 points (20.0%), fatigue 62 (13.3%), physical fitness 33 (7.1%), 
halting/ slowing damage 32 (6.9%) and quality of life/ wellbeing 29 (6.2%). 
 Representation of outcomes in existing composite measures 
It was not feasible to examine the representation of all 68 outcomes in the composite measures 
(CPDAI, PASDAS, GRACE, DAPSA). Examining the data there appeared to be a natural 
separation in the prioritisation of the top 10 ranked outcomes as compared to those ranked as 
less important (table 3). As a result the top ten ranked outcomes from the NGT were mapped 
to the composite measures and compared to the OMERACT core set of domains in Table 4. 
None of the existing composite measures captured all ten priority outcomes. Discussion at the 
investigators meeting focused on the two modular composites, the CPDAI and GRACE which 
are amenable to the additon of new outcomes. The top ten outcomes from the NGT are mapped 
to the CPDAI and GRACE in Figures 1 and 2 respectively. Pain (93 points) and fatigue (62 
points), were ranked considerably more important by patients than the other outcomes in the 
NGT, and it is notable that neither pain or fatigue are represented independently in the CPDAI 
or GRACE composte measures.  
 
The remaining eight out of the top ten outcomes identified in the NGT were then discussed. 
Physical function, quality of life and fitness were felt to be captured within the HAQ and 
PsAQol, ASQol. Damage is an important concept captured in the NGT and represented in the 
OMERACT core set of domains but given the irreversible nature of damage it was agreed this 
was not suitable to include in an activity measure, rather it should be measured seperately using 
a different instrument. Work, independence and mood are not independently or well captured 
in the existing composite activity measures. Of interest many of the outcomes not captured by 
the activity measures are reflected in the Psoriatic Arthritis Impact of Disease (PSAID) 
instrument (give reference) that was developed as a measure of impact rather than activity 
(Figures 1 and 2).25  Medication side effects are captured as adverse events in RCT’s but not 
in Longitudinal Observational Studies. The group recognised that it would not be feasible to 
add all outcomes in to a modified composite measure and that pain and fatigue appeared clearly 
separate in the rankings from other outcomes. It was also noted that pain and fatigue were 
included in the OMERACT core domain set and therefore there was agreement that they should 
be represented in the composite measures moving forward in a planned validation study, within 
the PROMPT programme.  
 
Potential measures for pain and fatigue were discussed. There are data supporting the use for 
the Functional Assessment of Chronic Illness – Fatigue (FACIT-Fatigue) patient reported 
questionnaire for physical fatigue in PsA.26 The PSAID instrument has fatigue and pain items 
(0-10) but the PSAID needs further validation as an activity measure.25 A standard pain Visual 
Analogue Scale 0-100 was also considered. It was agreed to incude these measures in the 
prospective study and select the best performing measure (in terms of sensitivity to change).  
 
Discussion  
We report a multicentre study ranking outcomes important to patients and how they are 
represented in existing composite measures of disease activity in PsA. None of the composite 
scores in their existing form capture the top ten outcomes important to patients identified in 
this study. Pain was ranked most highly by patients in this study and is not well represented in 
the existing composite measures. The DAPSA is the only composite to independently measure 
pain using a visual analogue scale. The CPDAI, GRACE and PASDAS may capture pain 
indirectly, such as through the tender joint count, enthesitis/ dactylitis counts, the patient global 
VAS score or within a component questionnaire. For example the CPDAI includes pain 
questions within the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)23 and the 
Ankylosing Spondylitis Quality of Life Index (ASQoL).24 However indirect measurement of 
an outcome in this way has disadvantages, such as the inability to perform specific analyses 
and reduced representation of an outcome within the overall score. The BASDAI, for example, 
is reported as single score and not by its component parts, making separate analysis of pain 
difficult. Deterioration of other components within the BASDAI (such as stiffness or fatigue) 
may also mask improvement in another component, in this case pain. Indirect measurement in 
this way also diminishes the representation of pain within the total composite score. Pain (the 
most highly ranked outcome to patients in this study) is included as a component of the 
BASDAI, as a subcomponent of the CPDAI, only contributes a small amount to the total score 
and therefore impacts on the face validity of the composite.   
 
Fatigue was ranked second highest by patients but, like pain, is not well represented in 
composite measures. Fatigue is also represented indirectly in the CPDAI (in the BASDAI and 
ASQoL) and PASDAS (PsAQoL).27 The individual questions of the BASDAI, ASQoL and 
PsAQoL are not designed to be separately reported and as a result fatigue cannot be easily 
studied independently. The same problem arises with independence which was ranked in the 
top ten outcomes and is represented in PsAQoL and ASQoL but not independently reported.  
 
Skin disease was ranked as a low priority in our study which is discordant with other qualitative 
studies of outcomes in PsA. The studies conducted for the development of the Psoriatic 
Arthritis Impact of Disease (PSAID) impact measure ranked skin symptoms as third highest 
behind pain and fatigue.25 In an international study to update the psoriatic arthritis OMERACT 
core set twenty four focus groups were conducted to identify domains of PsA important for 
patients as part of the update of the OMERACT core set for PsA.6 Skin psoriasis symptoms 
were ranked by patients as important but, as in our study, slightly lower than other outcomes 
(placed 17th  out of 39 in the first Delphi round, and 6th out of 15 in the second round).  The 
low ranking of skin symptoms in this study may reflect low levels of psoriasis amongst the 
cohort of patients in this study, but we did not specifically record participants levels of psoriasis 
activity before the focus groups. With regards to skin representation in the composite measures 
skin activity is captured in the GRACE, PASDAS and CPDAI but not in the DAPSA measures.  
 
We recognise that many of the outcomes important to patients in our study are captured in the 
PSAID impact measure. Outcomes identified as important to patients cover impact and activity 
supporting the view that patients do not distinguish between the two concepts when describing 
the influence of the disease.17 Only damage and treatment side effects are not included. The 
PSAID is a patient reported questionnaire in two versions, twelve or nine questions capturing 
aspects PsA such as pain, fatigue, work, function and participation. Therefore should the 
PSAID be validated as a measure of disease activity as well as impact?  
 
When interpreting the findings of this study it is important to recognise that concurrent 
fibromyalgia or depression amongst study participants was not recorded for sub-analysis. It is 
therefore not possible to determine the influence these comorbidities (or other contextual 
factors such as coping or self-management) on the NGT rankings. In a recent study by Brikman 
et al concomitant fibromyalgia was found to be associated with ‘worse’ scores in all patient 
reported, clinical and composite PsA measures.28 This is an important consideration when 
selecting (or modifying) a composite measure of disease activity where individual components 
of composite scores may be more susceptible to influence by contextual factors such as 
fibromyalgia.  
 
Composite activity measures are developed to capture all components of psoriatic arthritis 
disease activity, although component parts may be used to assess how individual aspects of 
disease are influenced by treatment. In a disease such as PsA, with diverse manifestations this 
is of considerable importance as, for example, a treatment may influence one domain but not 
another. A well-constructed composite measure should therefore capture all domains of disease 
yet allow sub-analysis of individual domains. Fatigue has been rated highly in the current study 
and now sits in the inner core of the recently updated OMERACT core set of domains.6 Little 
is understood about the underlying cause of fatigue in PsA or the effect of treatment, in large 
part because fatigue is infrequently measured in RCT’s.29 There is now an opportunity to 
incorporate pain and fatigue in a modified composite measure for PsA, either using the fatigue/ 
pain VAS scores from the PSAID questionnaire or the FACIT-fatigue scale.  
 
Conclusion 
In this NGT study we ranked outcomes of treatment important to patients and examined their 
representation in existing composite outcome measures that have been developed without 
significant input from patients. The top five outcomes ranked by patients were; pain with 93 
points (20.0%) and fatigue with 62 (13.3%), physical fitness 33 (7.1%), halting/ slowing 
damage 32 (6.9%) and quality of life/ wellbeing 29 (6.2%). Pain and fatigue were ranked most 
highly as outcomes important to patients and are not adequately captured within existing 
composite measures. Future work will focus on validating composite measures modified to 
capture outcomes important to patients. 
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OUTCOMES IDENTIFIED IN UK FOCUS GROUPS[17] 
1. Reduce the pain in my joints, for example hands, wrists, hips, and/or knees 
2. Reduce the pain in my back 
3. Reduce pulsating or sharp nerve pain, for example in my hands  
4. Reduce the pain in my muscles  
5. Reduce tenderness, for example tendons at back of my foot 
6. Reduce inflamed and burning joints  
7. Reduce swelling, for example in my hands and/or feet 
8. Reduce sausage toes and/or sausage fingers 
9. Reduce the variation in my body temperature  
10. Reduce stiffness, for example in my hands/thumbs, feet, and/or other joints 
11. Have less physical fatigue, for example not feel so tired 
12. Have less mental fatigue, for example be able to think more clearly  
13. Have less emotional fatigue, for example not get so cross and/or upset due to tiredness 
14. Have improved mobility, for example be able to walk more easily  
15. Have hands that do not lock or claw 
16. Have feet that do not feel so heavy 
17. Have increased strength, grip and dexterity in my hands 
18. Have less grinding and/or creaking in my bones and joints  
19. Have better/improved sleep 
20. Have skin that is less red 
21. Have skin that is less itchy and uncomfortable 
22. Have skin that is less flaky 
23. Have fewer fungal nail infections and\or split nails  
24. Have less variability in the different joints in my body that are affected on different days  
25. Have less variability in the number of my joints that are affected on different days 
26. Generally feel less unwell   
27. Not be in constant pain 
28. Have more stamina and/or energy 
29. Not lose the sense of touch and feeling in my fingers 
30. Not gain weight gain, for example due to reduced activity 
31. Not lose physical fitness 
32. Not have to cover up my skin in sunshine and/or wear high factor sun creams   
33. Feel in a better mood 
34. Feel less depressed 
35. Feel less anxious  
36. Feel less frustrated  
37. Feel less inadequate  
38. Feel less guilty  
39. Feel less angry  
40. Feel more confident   
41. Feel less embarrassed because of visible psoriasis   
42. Feel less isolated 
43. Be more sociable 
44. Feel more able to commit to activities and/or make plans 
45. Be able to keep up with my peers and/or friends  
46. Not sacrifice my home life  
47. Be able to remain in work  
48. Not have my work/job affected by my psoriatic arthritis  
49. Be able to maintain my independence/ not be dependent on others to help me   
50. Not feel nauseous and/or sick after taking treatments 
51. Not experience side effects (from treatments) 
52. Not be worried about long-term effects (of treatments) 
53. Not have reduced or lowered immunity (due to treatments)  
54. Not experience reduced concentration and/or brain fog after taking treatments   
55. Have treatments that I find easy to take 
56. Feel better after taking treatments, compared to before taking treatments 
57. Have treatments that do not interact with medications for other health conditions  
58. Have treatments that do not require regular monitoring and/or blood tests  
59. Halt/slow down the progression of my symptoms, for example not lose strength and/or flexibility in my joints  
60. Enable me to be and/or return to ‘normal’ 
61. Reduce the long-term damage to my joints  
62. Give me greater disease control, for example fewer flares 
63. Improve my quality of life and wellbeing  
 
ADDITIONAL OUTCOMES IDENTIFIED FROM INTERNATIONAL FOCUS GROUPS [6] 
64. Able to carry out my daily activities/tasks 
65. My condition is easier to self-manage (deal with) 
66. My condition has less impact on my role within the family 
67. Able to do my usual leisure activities 
68. Improved blood tests for inflammation  
 
Table 1  
List of 68 outcomes for discussion and ranking in round one of the NGT 
Group 1 Group 2 Group 3 Group 4 
 
Work  Treatments stop things deteriorating  Pain Pain –constant, dull 
Leisure activities Not to be in constant pain Fatigue  Mobility 
Daily activities  To maintain independence  Stiffness  Fatigue – emotional, mental, physical 
Quality of life – wellbeing Feeling less isolated  Sleep Quality of life  
Medicines side effects/interactions/immunity  Side effects of treatment  Emotions/anxiety/mood Impact and ability to work 
Feel better after treatment  Long terms effects of treatment  Mobility/walk Variability and control 
Physical fitness  Reduce pain in my muscles  Drug side effects/interactions  Being able to exercise more  
Touch and feeling in fingers  Frustrated  Less variability Side effects and lowered immunity 
Fatigue/stamina/mental fatigue  Variations in body temperature  Better immunity Grip, strength, dexterity 
Mobility Enable me to be/return to normal Skin Confidence, mood, emotions, depression 
Pain in back/joints Be able to remain in work Self-confidence  Weight 
Mood/anger/frustration Quality/continuity of clinician  Work Joint damage 
Stiffness Treatments that don’t interact with other 
medications  
Slow progression Pain –constant, dull 
Independence    
Self-management easier     
    
Group 5 Group 6 Group 7  
Treatments stop things deteriorating  Side effects/anxiety about symptoms Quality of life  
Not to be in constant pain Everyday activities Lose of sense of touch/feeling   
To maintain independence  Pain  Skin  
Feeling less isolated  Variability Sleep  
Side effects of treatment  Inflammation Pain  
Long terms effects of treatment  Fatigue (physical and mental) Frustration  
Reduce pain in my muscles  Burden of treatment (especially blood tests) Maintain independence   
Frustrated  Physical fitness and not gaining  weight  Lowered immunity   
Variations in body temperature  Impact on work Mobility/walk about more easily   
Enable me to be/return to normal Getting back to normal Flare (and anxiety about flare)  
Be able to remain in work Keeping up with peers Stress   
Quality/continuity of clinician  Mobility Fatigue – physical, mental 
(concentration), emotional 
 
Treatments that don’t interact with other 
medications  
Clearer skin (to avoid embarrassment because 
of other people) 
  
 
Table 2 Individual group shortlists of important outcomes from round two of the Nominal
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